slide1 n.
Skip this Video
Download Presentation

Loading in 2 Seconds...

play fullscreen
1 / 16

- PowerPoint PPT Presentation

  • Uploaded on

ERA-NET PathoGenoMics 2nd NSC & 3rd EB Meeting, April 07, 2005 Strategic supporting measures to raise synergies with the European framework programmes and to embed PathoGenoMics into the European R&D Landscape. National Contact Point LIFESCIHEALTH Dr. Wilfried Diekmann

I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
Download Presentation

PowerPoint Slideshow about '' - amy-daugherty

Download Now An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.

- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

ERA-NET PathoGenoMics

2nd NSC & 3rd EB Meeting, April 07, 2005

Strategic supporting measures

to raise synergies with the European framework programmes and to embed PathoGenoMics into the European R&D Landscape

National Contact Point LIFESCIHEALTH

Dr. Wilfried Diekmann

Königswinterer Str. 522-524, 53227 Bonn

phone: +49 228 447 698, e-mail:


a) Application-orientated genomic approaches

Brain and

diseases of

the nervous


Cardiovascular disease,


and rare


Human development


the ageing



tance to antibiotics

and other


b) Application of knowledge and technologies in the field of genomics and biotechnology for health

TP 1 Life Science, Genomics and Biotechnology for Health

Programme structure and pathogenomics-relevant areas

i) Advanced Genomics and its applications for health

a) Fundamental knowledge & basic tools for functional genomics in all organisms

Comparative genomics




Multidisciplinary functional genomics approaches to basic biological processes








Innovative research in post-genomics with

high potential for


New preventive and therapeutic tools

(somatic gene and cell

therapies; stem cell and immunotherapies, etc.)

New in vitro

tests to

replace animal



safer,more effective drugs

(incl. pharmaco-genomics)



ii) Combating major diseases

c) Poverty-

related diseases

b) Cancer

  • HIV / AIDS
  • Malaria
  • Tuberculosis

FP6 project portfolio in pathogenomics

Pathogenomics-relevant proposals to the 3rd Call



* based on panel priority lists, i.e. major priority lists of COM services are not yet available


FP6 project portfolio in pathogenomics

TP LSH, Fundamental Genomics, Outcome 3rd Call


Non-coding RNAs in bacterial pathogenicity (BACRNAs)

Major Priority List; Coordinator: University of Vienna, AT


Strategy to build up and maintain an integrated sustainable European fungal genomic database required for innovative genomics research on filamentous fungi important for biotechnology and human health (EUROFUNGBASE)

Major Priority List; Coordinator: Universiteit Leiden, NL


Major Priority ?

Reserve List ?

FP6 project portfolio in pathogenomics

TP LSH, Major Diseases, Outcome 3rd Call


Genomics to Combat Resistance against Antibiotics in Community-acquired Lower Respiratory Tract Infections in Europe (GRACE)

NI Panel Priority Order 10; Coordinator: Universiteit Antwerpen; BE


Combating resistance to antibiotics (CORANIX)

TI Panel Priority Order 7; Coordinator: Institut Pasteur, FR

Effects of antibiotic resistance on bacterial fitness, virulence and transmission


TI Panel Priority Order 9; Coordinator: Uppsala University, SE

Role of Mobile Genetic Elements in the Spread of Antimicrobial Drug

Resistance (DRESP2)

TI Panel Priority Order 10; Coordinator: Universita degli Studi di Siena, IT

Functional genomic characterisation of molecular determinants for

staphylococcal fitness, virulence and drug resistance (StaphDynamics)

TI Panel Priority Order 16; Coordinator: University of Groningen, NL


FP6 project portfolio in pathogenomics

TP LSH, Major Diseases, Outcome 3rd Call

Further STREPs passed the threshold:

Antifungal drug resistance in the human pathogen Candida glabrata (ANTIGLA)

TI Panel Priority Order 18; Coordinator: Instituto Superior Técnico, PT

Combating Candida drug resistance, CDR, by novel drugs especially acting

through interference with CDR regulatory network (CombatingCDR)

TI Panel Priority Order 19; Coordinator: Universität Bonn, DE

Factors affecting transfer and mobilization of extended spectrum beta-

lactamases (MOBILACT)

TI Panel Priority Order 21; Coordinator:University of Warwick, UK

ADaptation of VANComycin-resistant Enterococci and Staphylococci:

Ecological determinants of fitness and virulence


TI Panel Priority Order 22; Coordinator: University Medical Centre Utrecht, NL

Control of Resistance in Invasive Fungal Infection and Diagnosis (CRIFID)

TI Panel Priority Order 23; Coordinator: University Medical Centre Nijmegen, NL

Role of Genetic and Molecular Determinants in Survival and Spread of

Foodborne Antibiotic Resistant Bacteria (FoodRBug)

TI Panel Priority Order 25; Coordinator: University of Birmingham, UK


FP6 project portfolio in pathogenomics

TP LSH, Major Diseases (Cancer), Outcome 3rd Call


The role of chronic INfections in the development of CAncer (INCA)

NI Panel Priority Order 3; Coordinator: Medizinische Hochschule Hannover, DE

Linking Cancer Transcriptome to Proteome: Functional Oncogenomics for

Diagnosis and Treatment of Human Cancers related to Infectious Agents


NI Panel Priority Order 12; Coordinator: Fondazione Andrea Cesalpino, IT


FP6 project portfolio in pathogenomics

TP LSH, Poverty-related diseases (i.e. tuberculosis), Outcome 3rd Call


New medicines for tuberculosis (NM4TB)

NI Panel Priority Order 1; Coordinator: Institut Pasteur, FR

A Consortium for Tuberculosis Drug Development (TB-DD)

NI Panel Priority Order 7; Coordinator: University of Zürich, CH


Innate and adaptive immunity in clinical and experimental mycobacterial infection in neonates and infants (NEOTIM)

TI Panel Priority Order 5; Coordinator: Karolinska Institutet, SE

New drugs for persistent tuberculosis: Exploitation of 3-D structure of novel targets, lead optimisation and functional in vivo evaluation (NewTBDrugs)

TI Panel Priority Order 6; Coord.: LIONEX Diagnostics & Therapeutics GmbH, DE


Framework Programme 6, LIFESCIHEALTH

Fundamental Genomics, Topics for 4th Call

Gene expression and proteomics

A systems approach to understanding the regulation of gene transcription – IP

Structural genomics

Structural genomics interdisciplinary initiative – IP

Comparative genomics and population genetics

Functional genomics in Arabidopsis thaliana - IP

High throughput phenotyping tools and approaches for large scale functional

genomics studies – IP

Population cohorts for molecular epidemiological studies in European populations – IP

Multidisciplinary functional genomics approaches to basic biological processes

Functional genomics of autosomal aneuploid syndromes - IP

The biological role of small regulatory RNAs - IP

Specific Support Actions (SSAs)

Co-ordination Actions (CA)

Tools and technologies for functional genomics – STREP dedicated to SMEs


Framework Programme 6, LIFESCIHEALTH

Biotech & Applied Genomics, Topics for 4th Call

New, safer, more effective drugs including pharmacogenomics

Marker profiling as a new tool for predictive toxicology - IP

New tools to investigate ADME properties of drugs involving a carrier system – STREP

New diagnostics

High throughput molecular diagnostics for hereditary diseases - IP

Development of innovative methods for diagnosis of nervous system disorders – STREP

Nanoparticles-based diagnostics – STREP

New in vitro tests to replace animal experimentation

Predictive in vitro testing strategies for human exposure to chemicals - IP

Workshop on business opportunities for in vitro pharmaceutical toxicology – SSA

Researchers and regulators meet manufacturers of toxicology test methods – SSA

New preventive & therapeutic tools, somatic gene and cell therapies, stem cells, immunotherapies

Tissue engineering approaches to treating children with birth defects - IP

Hepatitis C vaccine - IP

Stem Cell Therapy for Stroke Patients – STREP

Methodological research to underpin stem cell banking - STREP

Use of baculovirus as a vector in gene therapy – STREP towards SME

Innovative research in post-genomics, which has high potential for application

Application of post-genomics to xenotransplantation research – IP

Approaches exploiting aquatic molecular biodiversity for biomedical applications - IP

Use of cell lines to define new bioassays for the identification of therapeutic biomolecules – STREP to SME

All areas – STREP dedicated to SMEs


Framework Programme 6, LIFESCIHEALTH

Major Diseases, Topics for 4th Call


General (overarching)

Genetic control of the pathogenesis of diseases based on iron metabolism – STREP

Combating, cardiovascular disease, diabetes and rare diseases

Genomic-wide mapping and functional genomics of susceptibility to coronary artery disease – IP

Hypertension and cardiovascular disease – NOE

Prevention of accelerated cardiovascular death in uraemia and end-stage renal disease - STREP

Functional genomics and regulatory networks in lipid metabolism & their effects on atherogenic

vascular disease development - STREP

Gene-environment interaction on the incidence of type 2 diabetes - IP

Molecular pathways underlying decreased beta cell mass in diabetes mellitus – STREP

Rare inherited neuromuscular disorders: from molecular basis to cutting edge therapies - NOE

Rare disorders of protein folding – STREP

Rare diseases of connective tissues affecting bone and/or cartilage – STREP

Research on cardiovascular and/or cerebrovascular disease – STREP towards SME

Preventive and therapeutic strategies for Type 1 diabetes – STREP towards SME

Development of in vitro and/or animal models for rare diseases – STREP towards SME


Framework Programme 6, LIFESCIHEALTH

Major Diseases, Topics for 4th Call

Combating resistance to antibiotics and other drugs

Control of antimicrobial resistance in hospital acquired and health care associated infections – IP

Molecular ecology of antibiotic drug resistance – IP

Workshop exploring novel opportunities towards vaccines and control of anti-bacterial resistance - SSA

New diagnostic tests for the management & control of antimicrobial resistance – STREP towards SME

Novel principles for anti-microbial treatment – STREP towards SME

Studying the brain and combating diseases of the nervous system

Functional genomics and neurobiology of epilepsy – IP

Neuroimaging: “Bridging genetics and neural function” – IP

Cortical information processing – STREP

Schizophrenia: from genotype to phenotype – STREP

Initiative in neuroinformatics – SSA

Neuroscience-oriented new technologies – STREP towards SME

Animal models for neurological and psychiatric diseases – STREP towards SME

Early markers and new targets for neurodegenerative diseases – STREP towards SME

Perinatal brain damage: early markers and neuroprotection – STREP towards SME

Studying human development and the ageing process

Integration of research in development and ageing - NOE

Attracting researchers to ageing research - SSA

Responsiveness of elderly people towards vaccination and infectious diseases – STREP towards SME


Framework Programme 6, LIFESCIHEALTH

Major Diseases (Cancer), Topics for 4th Call


Modulation of apoptosis in cancer prevention and therapy – IP

Broadening the knowledge base on the molecular mechanisms underlying chemotherapy

resistance, therapeutic escape, efficacy and toxicity – IP

Early diagnosis and novel therapies of solid childhood cancers – STREP

Innovative research on palliative care in patients with advanced stages of cancer – STREP

Role of chromosomal aberrations and epigenetic mechanisms of leukaemia – STREP

Identification and validation of biomarkers in molecular cancer epidemiology – STREP

Exploring the patient’s cancer stem cell as a novel therapeutic target – STREP

Conference on cell differentiation, plasticity and cancer – SSA

Innovative technological approaches for cancer therapy – STREP towards SMEs

Small-ligand libraries: improved tools for exploration and prospective anti-tumor therapy

- STREP towards SMEs

Improving resolution of current imaging devices relevant to cancer diagnosis and therapy

- STREP towards SMEs

Application of “molecular signatures” for the early diagnosis of cancer patients

- STREP towards SMEs


Framework Programme 6, LIFESCIHEALTH

Poverty-related diseases (PRD), Topics for 4th Call


HIV/AIDS Therapeutic Clinical trials network - NOE

HIV/AIDS Vaccines/Microbicides Network - NOE

Rationale Design of Malaria Vaccine - IP

New approaches for research into host/vector-pathogen interaction for HIV/AIDS, malaria and tuberculosis – STREP

Undesirable consequences of drugs and vaccines for Poverty-related Diseases – STREP

Integration & coordination of European clinical research on PRD - SSA/CA

Promotion of PRD research - SSA/CA

European Network for vaccine development covering the three diseases - SSA/CA

Improving participation of the private sector in PRD research – SSA towards SME

SME-driven innovations for poverty related diseases – STREP towards SME

Development of fast tests for diagnosis of poverty related diseases suitable for use in resource-poor settings – STREP towards SME

Innovative delivery mechanism for treatment and depot therapy in Poverty-related diseases – STREP towards SME


Framework Programme 6, LIFESCIHEALTH

Specific Support Actions across TP1; Topics for 4th Call

Promoting Collaboration between SMEs and Academia

Stimulating international co-operation

Promotion of cooperation with Associated Candidate Countries (ACC)

Realising ERA objectives

Life sciences and biotechnology – A strategy for Europe.

Supporting policy development

Scientific and project management

Mapping and identifying research efforts and contributions from FPs in the context of the European Community’s Public Health Programme, in the fields of health information, health threats and health determinants, with particular regard to mental health, reducing health risks, and preventing major as well as specific diseases.

Mapping and identifying research efforts and contributions from FPs in the context of the European Environment and Health Action Plan, in the fields of gene-environment interactions, respiratory diseases, neuro-developmental disorders, cardiovascular diseases and cancers, with particular regard to children’s health

Foresight study in the area of biotechnology and health

European human embryonic stem cell registry